


Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Cancel Claims 1-14

15. (New) A compound corresponding to formula (I) or a pharmaceutically acceptable salt or isomer thereof:



wherein:







A is CONH, NHCO, NHC(=S)NH, or NHC(=O)NH;

R₁ to R₄ is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a 5 or 6-member heterocyclic ring;

R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted

with at least one substituent selected from the group consisting of halogen atom, an amine group, and an alkyl group having 1 to 6 carbon atoms, provided that both of R_5 and R_6 are not hydrogen atoms simultaneously;

B is a group selected from




in which R_7 to R_{17} is independently a hydrogen atom, a halogen atom, or a straight or branched alkyl group having 1 to 6 carbon atoms optionally substituted with more than one halogen atom;

C is an alkyl, alkenyl, or alkynyl group having 1 to 5 carbon atoms which may include one or more heteroatoms, wherein each of m, n, p, q, r, and s is an integer of 0 to 3; and

an asteric mark * indicates a chiral carbon atom; and

(-----) mark indicates a double bond or single bond chain.

16. (New) A compound according to claim 15, corresponding to formula (II) or a pharmaceutically acceptable salt or isomer thereof:



wherein,

R_1 to R_4 is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring; and

R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atom, amine group and alkyl group having 1 to 6 carbon, provided that both of R₅ and R₆ are not hydrogen simultaneously

17. (New) A compound according to claim 16, wherein said compound is at least one selected from the group consisting of:

N-(4-tert-butylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (1-51, KMJ-372),

N-(4-tert-butylbenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (1-52, KMJ-470),

N-(4-tert-butylbenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide (1-53, SH-173),

N-(4-tert-butylbenzyl)-2-[3-iodo-4-(methylsulfonylamino)phenyl]propionamide (1-54, SH-168),

N-(4-tert-butylbenzyl)-2-[3,5-difluoro-4-(methylsulfonylamino)phenyl]propionamide (1-55, SH-285),

N-(4-tert-butylbenzyl)-2-[3-cyano-4-(methylsulfonylamino)phenyl]propionamide (1-56, SH-219),

N-(4-tert-butylbenzyl)-2-[3-methoxycarbonyl-4-

(methylsulfonylamino)phenyl]propionamide (1-57, JMJ-806),

N-(4-*tert*-butylbenzyl)-2-[3-carboxyl-4-

(methylsulfonylamino)phenyl]propionamide (1-58, KMJ-788),

N-4(*tert*-butylbenzyl)-2-[3-methoxycarbonyl-4-

(methylsulfonylamino)phenyl]propionamide (1-59, KMJ-838),

N-(4-*tert*-butylbenzyl)-2-[3-(benzylamino)carbonyl-4-

(methylsulfonylamino)phenyl]propionamide (1-60, KMJ-836),

N-(4-*tert*-butylbenzyl)-2-[3-piperidino-4-

(methylsulfonylamino)phenyl]propionamide (1-61, YS-65),

N-(4-*tert*-butylbenzyl)-2-[3-morpholino-4-

(methylsulfonylamino)phenyl]propionamide (1-62, YS-49),

N-(4-*tert*-butylbenzyl)-2-[3-(N-Boc)piperazino-4-

(methylsulfonylamino)phenyl]propionamide (1-63, YS-76),

N-(4-*tert*-butylbenzyl)-2-[3-piperazino-4-

(methylsulfonylamino)phenyl]propionamide (1-64, YS-79),

N-(4-*tert*-butylbenzyl)-2-[3-methoxy-4-

(methylsulfonylamino)phenyl]propionamide (1-65, CHK-717),

N-(4-*tert*-butylbenzyl)-2-[2-fluoro-4-

(methylsulfonylamino)phenyl]propionamide (1-66, KMJ-708),

N-(4-*tert*-butylbenzyl)-2-[2-chloro-4-

(methylsulfonylamino)phenyl]propionamide (1-67, KMJ-698),

N-(4-tert-butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-7, KMJ-750),
N-(4-chloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-8, YS-85),
N-(3,4-dichloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-9, YS-97),
N-(4-tert-butylbenzyl)-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (3-5, SU-834),
N-(4-tert-butylbenzyl)-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (3-6, SU-824),
N-(4-chlorobenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-1, SH-291),
N-(4-chlorobenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (4-2, SH-290),
N-(4-chlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide (4-3, SH-335),
N-(3,4-dichlorobenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-4, SH-94),
N-(3,4-dichlorobenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (4-5, SH-286),
N-(3,4-dichlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide (4-6, SH-337),
N-(4-methylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-7, SH-351),

N-(4-isopropylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-8, KMJ-928),

N-(4-methoxybenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-9, SH-353),

N-(4-trifluoromethylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]
propionamide (4-10, SH-93),

N-(4-phenylbenzyl)-2-(3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-1
1, KMJ-498),

N-(1-naphthylmethyl)-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-
12, SH-92),

N-(1,2,3,4-tetrahydro-1-naphthalenyl)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide (4-13, SH-112),

N-[2-(4-tert-butylphenyl)ethyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]
propionamide (4-14, KMJ-374),

N-[3-(3,4-dimethylphenyl)propyl]-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide (4-15, SU-770),

N-[3-(3,4-dimethylphenyl)propyl]-(2R)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide (4-16, SU-774),

N-[3-(3,4-dimethylphenyl)propyl]-(2S)-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide (4-17, SU-776),

N-[3-(3,4-dimethylphenyl)-2-propenyl]-2-[3-fluoro-4-
(methylsulfonylamino)phenyl]propionamide (4-18, KMJ-686),

N-[3-(4-chlorophenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-19, KMJ-518),
N-[3-(4-chlorophenyl)-2-propenyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-20, KMJ-732),
N-benzyloxy-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-21, SH-109),
N-(benzhydryl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-22, SH-130),
N-(2,2-diphenylethyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-23, SH-116),
N-(3,3-diphenylpropyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-24, KMJ-378),
N-(3,3-diphenyl-2-propenyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-25, KMJ-724),
N-[3,3-di(4-methylphenyl)-2-propenyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-26, KMJ-908),
N-[3,3-di(4-fluorophenyl)-2-propenyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-27, SH-135),
N-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yliden)ethyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-28, SH-199),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]propionamide (5-1, CHK-512),


N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]propionamide (5-2,CHK-514),
2-[3-fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]propionamide (5-3,SU-542),
2-[3-fluoro-4-(methylsulfonylamino)phenyl]-N-[2-4-tert-butylbenzyl)-3-pivaloxypropyl]propionamide (5-4,SU-564),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]propionamide (5-5,CHK-479),
N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-methylsulfonylamino)phenyl]propionamide (5-6,CHK-499),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (5-7,KNJ-472),
N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (5-8, KMJ-690),
N-[(1R)-1-benzyl-2-(pivaloxy)ethyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-1, SU-730)*
N-[(1S)-1-benzyl-2-(pivaloxy)ethyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-2, SU-634),
N-[(1S)-1-benzyl-2-(pivaloxy)ethyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-3, SU-636),

N-[(1R)-1-benzyl-2-(pivaloxy)ethyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-4, SU-728),
N-[(2R)-2-benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-5, SU-826),
N-[(2S)-2-benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-6, SU-830),
N-[(2S)-2-benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-7, SU-838),
N-[(2R)-2-benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-8, SU-818),
N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-9, MK-271),
N-[(2S)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-10, MK-272),
N-[(2S)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-11, MK-450),
N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-12, MK-452),
N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-13, MK-453),
N-[(2S)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-14, MK-451),

2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2-methylpropionic acid (7-4, CHK-624),
2-(4-(methylsulfonylamino)phenyl)-2-methylpropionic acid (8-11),
2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionic acid (8-12),
N-[2-(3, 4-dimethylbenzyl)-3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-1, CHK-520),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-2, CHK-543),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-3, CHK-493),
N-[3-(3,4-dimethylphenyl)propyl]-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-4, CHK-591),
N-[3-(3,4-dimethylphenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-5, CHK-656),
N-[3-(3,4-dimethylphenyl)propyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-6, CHK-600),
N-(4-tert-butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-7, CHK- 715),
N-(4-tert-butylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-8, CHK-655),
N-(4-tert-butylbenzyl)-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-9),

1-[3-fluoro-4-(methylsulfonylamino)phenyl]cyclopropane carboxylic acid (10-5),
1-[4-(methylsulfonylamino)phenyl]cyclopropane carboxylic acid (11-7, CHK-530),
1-[3-methoxy-4-(methylsulfonylamino)phenyl]cyclopropane carboxylic acid (11-8),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-1-[4-(methylsulfonylamino)phenyl]
cyclopropane carboxamide (12-1, CHK-533),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-1-[3-fluoro-4-
(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-2, CHK-538),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-1-[3-methoxy-4-
(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-3, CHK-541),
N-[3-(3,4-dimethylphenyl)propyl]-1-[4-
(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-4, CHK-590),
N-[3-(3,4-dimethylphenyl)propyl]-1-[3-fluoro-4-
(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-5),
N-[3-(3,4-dimethylphenyl)propyl]-1-[3-methoxy-4-(methylsulfonylamino)-
phenyl]cyclopropane carboxamide (12-6, CHK-632),
N-(4-*tert*-butylbenzyl)-1-[4-(methylsulfonylamino)phenyl]cyclopropane
carboxamide (12-7, CHK-719),
N-(4-*tert*-butylbenzyl)-1-[3-fluoro-4-(methylsulfonylamino)phenyl]cyclopropane
carboxamide (12-8, CHK-659),
and N-(4-*tert*-butylbenzyl)-1-[3-methoxy-4-
(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-9, CHK-718).

18. (New) A compound according to claim 15, corresponding to formula (III), or a pharmaceutically acceptable salt or an isomer thereof:



wherein

R₁ to R₄ is independently hydrogen, halogen, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring, provided that all of R₁ to R₄ are not hydrogen atoms simultaneously; and

R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atom, amine group and alkyl group having 1 to 6 carbons, provided that both of R₅ and R₆ are not a hydrogen atom simultaneously.

19. (New) A compound according to claim 18, wherein said compound is selected from the group consisting of:

N-(4-tert-butylbenzyl)-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl} thiourea (15-1, LJO-328),

N-(4-tert-butylbenzyl)-N'-{1-[3-chloro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (15-2, CHK-992),

N-(4-tert-butylbenzyl)-N'-{1[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl} thiourea (15-3, CHK-575),

N-(4-tert-butylbenzyl)-N'-{1-[3-(methoxycarbonyl)-4-(methylsulfonylamino)phenyl]ethyl}thiourea (15-4, YHS-187),

N-(4-tert-butylbenzyl)-N'-{1-[3-carboxy-4-(methylsulfonylamino)phenyl]ethyl} thiourea (15-5, YHS-209),

N-(4-tert-butylbenzyl)-N'-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl} thiourea (16-5, SU-388),

N-(4-tert-butylbenzyl)-N'-{(1S)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (16-6, SU-400),

N-(4-tert-butylbenzyl)-N'-{(1R)-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (17-3, CJU-032),

N-(4-tert-butylbenzyl)-N'-{(1S)-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (17-6, CJU-039),


N-[(2R)-2-benzyl-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-1, MK-229),

N-[(2S)-2-benzyl-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-2, MK-202),
N-[(2R)-2-benzyl-3-(pivaloyloxy)propyl]-N'-1(1S)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-3, MK-230),
N-[(2S)-2-benzyl-3-(pivaloyloxy)propyl]-N'-{(1S)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-4, MK-228),
N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-5, LJO-388),
N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-6, SU-472),
N-[(2R)-2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-7, SU-512),
N-[(2S)-2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-8),
N-[2-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-9, LJO-401),
N-[2-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1(R)-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-10, MK-296),
N-[2(R)-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1(R)-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-11, MK-334),
N-[2(S)-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1(R)-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-12, MK-298),

N-[2-(3,4-(dimethylbenzyl)-3-(pivaloyloxy)propyl)-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-13, LJO-344),
N-[2-(4-*tert*-butylbenzyl)-3-(pivaloyloxy)propyl)-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-14, LJO-366),
N-[(2R)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(R)- α -methyl-4-(methylsulfonylamino)benzyl]thiourea (19-13, SU-692),
N-[(2S)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(R)- α -methyl-4-(methylsulfonylamino)benzyl]thiourea (19-14, SU-704),
N-[(2R)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(S)- α -methyl-4-(methylsulfonylamino)benzyl]thiourea (19-15, SU-720),
N-[(2S)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(S)- α -methyl-4-(methylsulfonylamino)benzyl]thiourea (19-16, SU-710),
N-(4-*tert*-butylbenzyl)-N'-{1-4-(methylsulfonylamino)-3-fluorophenyl}propyl}thiourea (20-12, LJO-399),
N-(4-*tert*-butylbenzyl)-N'-{1-[4-(methylsulfonylamino)-3-fluorophenyl]-2-methylpropyl}thiourea (20-13, LJO-402),
N-(4-*tert*-butylbenzyl)-N'-{[4-(methylsulfonylamino)-3-fluorophenyl](phenyl)methyl}thiourea (20-14, LJO-403),
N-4-*tert*-butylbenzyl)-N'-{1-[4-(methylsulfonylamino)-3-fluorophenyl]-2-phenylethyl}thiourea (20-15, LJO-395),
N-(4-*tert*-butylbenzyl)-N'-{1-methyl-1-[4-(methylsulfonylamino)phenyl]-ethyl}thiourea (21-7, CHK-593),

N-(4-*tert*-butylbenzyl)-N'-{1-methyl-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (21-8, CHK-660),
N-(4-*tert*-butylbenzyl)-N'-{1-methyl-1-[3-methoxy-4-methylsulfonylamino)phenyl]ethyl}thiourea (21-9, CHK-629),
N-(4-*tert*-butylbenzyl)-N'-{1-[4-(methylsulfonylamino)phenyl]cyclopropyl}thiourea (22-7, CHK-579),
N-(4-*tert*-butylbenzyl)-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]cyclopropyl}thiourea (22-8), and
N-(4-*tert*-butylbenzyl)-N'-{1-[3-methoxy-4-(methylsulfonylamino)phenyl]cyclopropyl}thiourea (22-9, CHK-631).

21. (New) A compound according to claim 15, corresponding to formula (IV), or a pharmaceutically acceptable salt or isomer thereof :



wherein,

R₁ to R₄ is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide

group having 1 to 6 carbon atoms, benzylamide group, or five or six-member heterocyclic ring; and


R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of a halogen atom, amine group and alkyl group having 1 to 6 carbons, provided that both of R₅ and R₆ are not hydrogen atoms simultaneously.

21. (New) A compound according to claim 20, wherein said compound is

N-(4-*tert*-butylbenzyl)-N'-1-[4-(methylsulfonylamino)phenyl]ethyl}urea (23-1, MK-82), or

N-(4-*tert*-butylbenzyl)-N'-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-urea (23-2, MK-205).

22. (New) A compound according to claim 15, corresponding to formula (V), or a pharmaceutically acceptable salt or isomer thereof :



wherein,

R₁ to R₄ is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring; and

R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atoms, amine groups and alkyl groups having 1 to 6 carbons, provided that both of R₅ and R₆ are not hydrogen atoms simultaneously.

23. (New) A compound according to claim 22, wherein said compound is selected from the group consisting of:

N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)-acetamide (24-1, KMJ-586),

N-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)propanamide (24-2, KMJ-552),

N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)-2-propanamide (24-3, KMJ-570),

N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)propanamide (24-4, CHK-602),

N-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)-2-propanamide (24-5, CHK-651),

N-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)propanamide (24-6, CHK-534),

N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-chlorophenyl)-2-propanamide (24-7, KMJ-558), and

N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)-butanamide (24-8, CHK-647).

24. (New) A compound according to claim 15, wherein R₁ to R₄ is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring.

25. (New) A compound according to claim 15, wherein R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of a halogen atom, amine group or an alkyl group having 1 to 6 carbons.

26. (New) A pharmaceutical composition comprising a compound according to claim 15 as an active ingredient in an effective vanilloid receptor antagonizing amount, together with a pharmaceutically acceptable carrier or diluent.

27. (New) A method of treating acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder, irritation of skin, eye or mucous membrane, fervescence, coughing, stomach-duodenal ulcer, or inflammatory bowel disease caused by the vanilloid receptor antagonistic activity, in a patient suffering therefrom, said method comprising administering to said patient a pharmaceutically effective amount of at least one compound according to claim 15.

28. (New) Method of treating or inhibiting pain or inflammation, in a patient suffering therefrom, said method comprising administering to said patient a pharmaceutically effective amount of at least one compound according to claim 15.

29. (New) The pharmaceutical composition according to claim 27, wherein the respiratory disorder is asthma or method of treating asthma or chronic obstructive pulmonary disease, in a patient suffering therefrom, said method comprising administering to said patient a pharmaceutically effective amount of at least one compound according to claim 15.